Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Raised by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 24.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 57,300 shares of the biopharmaceutical company’s stock after purchasing an additional 11,200 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Halozyme Therapeutics were worth $3,278,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in HALO. Neo Ivy Capital Management purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at $207,000. Virtu Financial LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $607,000. Congress Asset Management Co. MA lifted its position in shares of Halozyme Therapeutics by 15.6% in the 4th quarter. Congress Asset Management Co. MA now owns 351,076 shares of the biopharmaceutical company’s stock valued at $12,976,000 after acquiring an additional 47,359 shares in the last quarter. Wellington Management Group LLP boosted its stake in Halozyme Therapeutics by 16.1% in the 4th quarter. Wellington Management Group LLP now owns 180,856 shares of the biopharmaceutical company’s stock worth $6,684,000 after purchasing an additional 25,125 shares during the period. Finally, Fisher Asset Management LLC grew its position in Halozyme Therapeutics by 0.6% during the 4th quarter. Fisher Asset Management LLC now owns 276,902 shares of the biopharmaceutical company’s stock worth $10,234,000 after purchasing an additional 1,667 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HALO shares. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, October 4th. Benchmark reaffirmed a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. The Goldman Sachs Group increased their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Morgan Stanley boosted their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.44.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $53.00 on Friday. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The firm has a fifty day simple moving average of $58.73 and a 200-day simple moving average of $50.71. The stock has a market capitalization of $6.71 billion, a price-to-earnings ratio of 20.54, a PEG ratio of 0.49 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. During the same quarter in the previous year, the business earned $0.68 EPS. The business’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total transaction of $551,200.00. Following the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $9,269,861.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $55.12, for a total transaction of $551,200.00. Following the sale, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at $9,269,861.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the transaction, the chief financial officer now directly owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,881 shares of company stock valued at $5,458,084. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.